Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615488 | 0.92 | MMP2 (0.40) | HRH2HRH1STSKDM1AMMP2 | |
| SCHEMBL15583841 | 0.82 | PDE3B (0.43) | STSKDM1AMMP2MAPTMMP3 | |
| SCHEMBL15823025 | 0.81 | CYP1A1 (0.51) | HRH2HRH1STSKDM1AMAPT | |
| SCHEMBL15588886 | 0.80 | PDE3B (0.44) | STSKDM1AMMP2MAPTMMP3 | |
| SCHEMBL12841314 | 0.79 | MMP2 (0.51) | HRH2HRH1MMP2MMP3 | |
| SCHEMBL16941030 | 0.79 | KDM1A (0.50) | HRH2HRH1STSKDM1AMMP2 | |
| SCHEMBL16946006 | 0.78 | HRH2 (0.46) | HRH2HRH1MMP2MAPTMMP3 | |
| SCHEMBL17974605 | 0.77 | KIF11 (0.46) | STSKDM1AMMP2MAPTMMP3 | |
| SCHEMBL7634772 | 0.77 | ALDH1A1 (0.48) | HRH2HRH1MMP3CYP11B2CYP11B1 | |
| SCHEMBL14531566 | 0.77 | ALDH1A1 (0.41) | HRH2HRH1MAPTCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9644144-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| EP-2890762-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160222293-A1 | MESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2015043713-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MTX1, NEFM, MTX2 | HRH2 3986/4885HRH1 3664/4885STS 2277/4885 |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | HRH2 3001/4885HRH1 2126/4885STS 2719/4885 |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | HRH2 3001/4885HRH1 2126/4885STS 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.